Kathleen Lamborn | Academic Influence

Kathleen Lamborn's AcademicInfluence.com Rankings

Kathleen Lamborn

Mathematics

#7127

World Rank

#9751

Historical Rank

Statistics

#817

World Rank

#907

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Kathleen Lamborn's Degrees

Bachelors Mathematics Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Kathleen Lamborn Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Kathleen Rundle Lamborn is an American biostatistician, known for her highly-cited publications on glioma. She is an Adjunct Professor Emeritus of Neurological Surgery and former Director of the Cancer Center Biostatistics Core at the University of California, San Francisco, and Senior Scientific Consultant at Quintiles Pacific.

(See a Problem?)

Kathleen Lamborn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010) (2448)
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. (2008) (1135)
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. (2005) (508)
Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. (2001) (489)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. (2005) (477)
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. (2004) (465)
Seizure characteristics and control following resection in 332 patients with low-grade gliomas. (2008) (460)
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 (2006) (428)
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. (1998) (403)
Radiosurgery for brain metastases: is whole brain radiotherapy necessary? (1999) (401)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme (2005) (389)
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. (2008) (375)
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. (2009) (371)
Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. (2004) (367)
Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. (1998) (351)
Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. (2004) (339)
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. (2012) (290)
Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. (2001) (288)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. (2010) (271)
Second cancers following pediatric Hodgkin's disease. (1998) (254)
Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. (1997) (253)
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 (2005) (241)
Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging (2007) (238)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. (2006) (225)
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. (2006) (223)
Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. (2006) (214)
Dose conformity of gamma knife radiosurgery and risk factors for complications. (2001) (211)
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. (2008) (210)
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. (2011) (204)
Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts (2002) (203)
Genetic control of platelet and plasma monoamine oxidase activity. (1973) (202)
High activity iodine-125 interstitial implant for gliomas. (1992) (201)
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). (2010) (193)
Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. (1998) (191)
A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. (1999) (188)
Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors (2002) (183)
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. (2002) (179)
A multicenter, prospective pilot study of gamma knife radiosurgery for mesial temporal lobe epilepsy: Seizure response, adverse events, and verbal memory (2009) (172)
Changes in Transcranial Motor Evoked Potentials during Intramedullary Spinal Cord Tumor Resection Correlate with Postoperative Motor Function (2005) (170)
Radiation response and survival time in patients with glioblastoma multiforme. (1996) (167)
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. (2007) (158)
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen (1997) (157)
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. (2006) (155)
Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. (2008) (154)
Role of infection in chronic bronchitis. (1976) (153)
The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial. (1973) (149)
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy (2008) (148)
Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. (1999) (147)
Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. (2002) (146)
Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. (2007) (145)
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. (2004) (138)
Apoptosis in the subependyma of young adult rats after single and fractionated doses of X-rays. (1997) (137)
Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. (2001) (136)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. (1992) (136)
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). (2009) (134)
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. (2008) (133)
Gamma knife for glioma: selection factors and survival. (1996) (128)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. (2014) (127)
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. (2001) (126)
The superiority of conservative resection and adjuvant radiation for craniopharyngiomas (2012) (126)
Long-Term Impairment of Subependymal Repopulation Following Damage by Ionizing Irradiation (1999) (122)
Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. (1992) (120)
Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. (2002) (120)
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. (2004) (120)
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study (2009) (120)
A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. (2000) (119)
Clinical trial end points for high-grade glioma: the evolving landscape. (2011) (117)
A multiple-dose, controlled study of phenelzine in depression-anxiety states. (1976) (116)
Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. (1997) (116)
Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. (2005) (115)
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. (2006) (115)
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. (2009) (114)
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM (2009) (109)
Hippocampal Neurogenesis and Neuroinflammation after Cranial Irradiation with 56Fe Particles (2008) (109)
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. (2013) (109)
Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. (2008) (108)
Delayed Surgical Resection Reduces Intraoperative Blood Loss for Embolized Meningiomas (2002) (107)
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. (2012) (106)
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. (1998) (106)
VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. (2002) (106)
Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. (2002) (102)
Radiosurgery for brain metastases from primary lung carcinoma. (2001) (101)
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05) (2008) (98)
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. (2011) (96)
A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. (2001) (95)
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? (2011) (93)
Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade (1998) (89)
Temozolomide in the treatment of recurrent malignant glioma (2004) (89)
Coregistration Accuracy and Detection of Brain Shift Using Intraoperative Sononavigation during Resection of Hemispheric Tumors (2003) (89)
Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. (2006) (87)
Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. (2002) (86)
Gliomatosis Cerebri: A Review of 22 Cases (2003) (85)
Image-Guided Robotic Stereotactic Body Radiotherapy for Benign Spinal Tumors: The University of California San Francisco Preliminary Experience (2007) (84)
Phase II study of paclitaxel in patients with recurrent malignant glioma. (1996) (84)
Radiation therapy for intracranial germ cell tumors. (2003) (84)
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. (2010) (84)
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. (1995) (83)
A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. (1999) (83)
Natural history of anal cytologic abnormalities and papillomavirus infection among homosexual men with group IV HIV disease. (1992) (80)
Medulloblastoma in adults. (1995) (80)
Influence of a child's sex on medulloblastoma outcome. (1998) (79)
Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma (2007) (78)
Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. (2000) (78)
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. (2011) (78)
Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. (2004) (77)
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas (2008) (75)
Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. (2012) (74)
Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma (2005) (74)
Comparison of monoamine oxidase substrate activities in twins, schizophrenics, depressives, and controls. (1974) (74)
Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. (1995) (74)
Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. (1997) (73)
Quality of life in low-grade glioma patients receiving temozolomide. (2009) (73)
High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody (2005) (73)
Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia. (2002) (71)
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 (2002) (69)
Annexin II marks astrocytic brain tumors of high histologic grade. (1994) (69)
Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. (2001) (68)
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival (2009) (68)
Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. (1997) (67)
Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors (2005) (67)
Factors influencing survival after gamma knife radiosurgery for patients with single and multiple brain metastases. (1996) (67)
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. (1998) (66)
Repeated operations for infiltrative low-grade gliomas without intervening therapy. (2003) (65)
Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. (1996) (64)
Conditional probability of survival in patients with newly diagnosed glioblastoma. (2011) (64)
Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. (2013) (64)
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme (2007) (64)
Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. (1998) (63)
Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment (2012) (63)
Radiation-induced reductions in neurogenesis are ameliorated in mice deficient in CuZnSOD or MnSOD. (2009) (63)
Neuropsychological outcomes after Gamma Knife radiosurgery for mesial temporal lobe epilepsy: A prospective multicenter study (2011) (63)
Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. (2001) (61)
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. (2000) (61)
Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study. (1999) (61)
Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. (2005) (60)
The biologic window for chimeric l6 radioimmunotherapy (1994) (60)
Grade II astrocytomas are subgrouped by chromosome aberrations. (2003) (56)
NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. (2004) (55)
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 (2012) (55)
Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 (2008) (55)
Suprasellar Rathke Cleft Cysts: Clinical Presentation and Treatment Outcomes (2011) (55)
Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? (2006) (54)
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. (2005) (53)
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. (2003) (52)
Identifying the needs of brain tumor patients and their caregivers (2011) (50)
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. (2007) (50)
Relationship between pattern of enhancement and local control of brain metastases after radiosurgery. (2001) (50)
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. (2010) (49)
Proliferative potential and prognostic evaluation of low-grade astrocytomas (2005) (48)
Incidence of venous thromboembolism in patients undergoing craniotomy and motor mapping for glioma without intraoperative mechanical prophylaxis to the contralateral leg. (2003) (48)
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. (2012) (47)
The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. (1995) (47)
Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. (2004) (46)
Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas (2009) (46)
Adult medulloblastoma: an analysis of survival and prognostic factors. (1997) (46)
Killing of brain tumor cells by hypoxia-responsive element mediated expression of BAX. (1999) (44)
Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas (2009) (44)
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. (2010) (43)
Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (1999) (43)
Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. (1986) (42)
Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. (1999) (42)
Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. (1998) (42)
Synthesis and comparative toxicology of a series of polyhedral borane anion-substituted tetraphenyl porphyrins. (2007) (39)
Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. (2002) (39)
Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. (1996) (38)
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. (2008) (38)
Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. (2009) (38)
Bromophenol Blue Staining of Tumors in a Rat Glioma Model (2005) (37)
Late consolidative radiation therapy in the treatment of limited‐stage small cell lung cancer (1991) (36)
Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. (1991) (36)
Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). (2016) (36)
Multiple genetic aberrations including evidence of chromosome 11q13 rearrangement detected in pituitary adenomas by comparative genomic hybridization. (1999) (36)
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. (2010) (35)
The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. (2006) (34)
A design of phase II cancer trials using total and complete response endpoints (2005) (33)
Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. (2003) (33)
Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04–02) (2007) (32)
67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma. (1999) (32)
GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. (1996) (32)
Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies. (1997) (32)
Growth of human glioblastomas as xenografts in the brains of athymic rats. (2002) (31)
Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss. (2012) (31)
A statistical approach for analyzing clonogenic survival data. (1996) (31)
Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. (2007) (31)
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. (2005) (30)
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. (2011) (30)
Synergistic therapy of breast cancer with Y-90-chimeric L6 and paclitaxel in the xenografted mouse model: development of a clinical protocol. (1998) (28)
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma (1997) (28)
Critical Lym-1 binding residues on polymorphic HLA-DR molecules. (1999) (28)
Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. (1998) (27)
Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. (2008) (27)
Treatment of acute shoulder syndrome with flurbiprofen. (1986) (27)
Microglial responses after focal radiation-induced injury are affected by alpha-difluoromethylornithine. (1996) (25)
Reproducibility of operator processing for radiation dosimetry. (1997) (25)
Bromodeoxyuridine labeling index in glioblastoma multiforme: relation to radiation response, age, and survival. (1996) (24)
Proximity of Spinous/Paraspinous Radiosurgery Metastatic Targets to the Spinal Cord Versus Risk of Local Failure (2007) (24)
Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures. (2006) (23)
Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer. (1986) (23)
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update (2010) (23)
Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy. (1996) (23)
High failure rate in spinal ependymomas with long-term follow-up. (2004) (22)
Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1 (1995) (22)
Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. (2007) (21)
Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study (2007) (21)
In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts. (2004) (21)
Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme (2007) (20)
Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. (2007) (20)
Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. (1986) (20)
Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model. (2005) (20)
Detection of hypoxia in human brain tumor xenografts using a modified comet assay. (2003) (19)
Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy (2005) (19)
The Ways and Means of Statistics (1979) (19)
Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. (2003) (19)
Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. (2003) (19)
Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. (2003) (18)
Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin. (1986) (18)
Prognostic factors for radioimmunotherapy in patients with B-lymphocytic malignancies. (1994) (17)
Quantification of iodine-131 in tumors using a threshold based on image contrast (1998) (17)
Long-term follow-up after high-activity 125I brachytherapy for pediatric brain tumors. (1996) (16)
Modification of Radiation-Induced Brain Injury by α-Difluoromethylornithine (1991) (16)
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. (1995) (16)
Plasma tricyclic drug levels in amitriptyline-treated depressed patients (1979) (16)
Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). (2009) (16)
Signal transduction molecules in gliomas of all grades (2007) (16)
Intrauterine Contraceptive Device and Increased Serum Immunoglobulin Levels (1973) (15)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). (2009) (14)
Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study (2005) (14)
Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers? (2005) (13)
Characterization of human glioblastoma xenograft growth in athymic mice. (1998) (13)
Snowmobiling: characteristics of owners, patterns of use and injuries†☆ (1975) (12)
Final report on the University of California‐San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients (1999) (12)
Expression of the Hypoxia Marker Carbonic Anhydrase 9 Is Associated with Anaplastic Phenotypes in Meningiomas (2007) (12)
Flurbiprofen in the treatment of rheumatoid arthritis. A comparison with aspirin. (1986) (12)
Targeting glioma-initiating cells in GBM: ABTC-0904, a randomized phase 0/II study targeting the Sonic Hedgehog-signaling pathway. (2014) (12)
Proceedings: Comparison of MAO substrate activities in twins, schizophrenics, depressives, and controls. (1974) (12)
Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging. (2012) (12)
A phase I / II trial of the histone deacetylase inhibitor , romidepsin , for adults with recurrent malignant glioma : North American Brain Tumor Consortium Study 0303 (2011) (12)
Phase II study of imatinib mesylate (ST1571) for patients with recurrent meningiomas (NABTC 01-08) (2006) (11)
Treatment of osteoarthritis of the knee. A comparison of flurbiprofen and aspirin. (1986) (11)
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. (2000) (11)
Marihuana and driving among teenagers: Reported use patterns, effects, and experiences related to driving☆ (1974) (11)
Visual field defects after radiosurgery for mesial temporal lobe epilepsy (2013) (11)
Characterization of human IgG antimouse antibody in patients with B-cell malignancies. (2003) (10)
Effects of Matrigel on the SF-767 malignant glioma athymic mouse tumor model. (1997) (10)
Hypoxia-Induced BAX Overexpression and Radiation Killing of Hypoxic Glioblastoma Cells (2005) (10)
Measurement of radiation-induced damage in human glioma cells with flow cytometry. (1996) (10)
Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) (2008) (9)
Phase II study of POLY-ICLC in recurrent anaplastic glioma-A North American Brain Tumor Consortium study. (2006) (9)
Aberrant p 53 , mdm 2 , and Proliferation Differ in Glioblastomas from Long-Term Compared with Typical Survivors 1 (2002) (9)
Ongoing clinical trials. (2003) (9)
Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer (1992) (9)
A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma. (2011) (8)
Proliferation markers in gliomas: A comparison of BUDR, KI-67, and MIB-1 (2005) (8)
Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas (1990) (7)
Radiopotentiation of human brain tumor cells by sodium phenylacetate. (1999) (7)
Cerebrovascular effects of the bradykinin analog RMP-7 in normal and irradiated dog brain (1998) (7)
Hypoxia-inducible expression of BAX: application in tumor-targeted gene therapy (2000) (7)
Radiation in pediatric Hodgkin's disease. (1998) (6)
Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. (2011) (5)
The role of radiation for pediatric low-grade gliomas (2002) (5)
Modification of radiation-induced brain injury by alpha-difluoromethylornithine. (1991) (5)
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. (2020) (5)
Interaction between sorafenib and erlotinib. (2009) (5)
Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma (2007) (5)
The use of circulating rosette-forming cells as a guide to determination of ATG dose (dose-by-rosette). (1978) (5)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors : Tissue Analysis fromNorth (2005) (4)
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM). (2013) (4)
Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation therapy in patients with glioblastoma multiforme or gliosarcoma. (2009) (4)
Treatment for posterior fossa dissemination of primary supratentorial glioma. (2007) (4)
Safety of flurbiprofen in the treatment of ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis. A summary of liver and kidney assay data. (1986) (4)
A prospective study of radiation therapy-associated thrombocytopenia. (1997) (4)
Stereotaxic interstitial iodine-125 “boost” in the initial management of malignant gliomas (1990) (3)
Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. (2011) (3)
Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. (2011) (3)
Radiation-induced DNA double-strand breaks and rejoining in malignant glioma cells. (1999) (3)
125 Hyperfractionated radiotherapy of medulloblastoma (1999) (3)
The role of craniospinal radiation in the treatment of intracranial germ cell tumors (2001) (2)
MAO inhibitors in clinical practice: principles based on recent research [proceedings]. (1977) (2)
Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma (2007) (2)
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. (2007) (2)
Low-density lipoprotein receptor expression in human glioblastoma (2003) (2)
Toxicology of BOPP in Large Animals (2001) (1)
P41 01 TP – THE IMPORTANCE OF THERMAL DOSE IN THE OUTCOME OF ERAIN THERMORADIOTHERAPY (1991) (1)
Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation in patients with GBM. (2010) (1)
Scientific Program 20th Annual Meeting of the American Society of Pediatric Neurosurgeons (1996) (1)
Chapter 28 – Gliomatosis Cerebri (2005) (1)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma 1 (2005) (1)
Induction of abortion by intramuscular administration of (15S)-15-methyl PGF2 alpha. An overview of 815 cases. (1979) (1)
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas. (2016) (1)
Phase I/pharmacokinetic study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma (2007) (1)
Long-Term Outcomes for Pediatric Low-Grade Hypothalamic/Chiasmatic Gliomas Treated on Phase II Chemotherapy Trial (2007) (1)
Phase II study of salvage therapy with high-dose tamoxifen and oral etoposide for recurrent malignant glioma (2004) (1)
In reference to lamborn et Al. (Neuro-oncology. 2008;10:162-170). (2008) (1)
The Ways and Means of Statistics.@@@Introductory Statistics. (1980) (0)
1017 Radiosurgery for brain metastases: Is whole brain radiation therapy necessary? (1996) (0)
10 Prognostic factors associated with radiosurgery for malignant glioma: Results of a multi institutional Gamma Knife study (1995) (0)
Quantitative description of dose conformality achieved by gamma knife radiosurgery compared to linac radiosurgery (2000) (0)
Phase II study of TPDCV in childhood. Medulloblastoma, anaplastic ependymoma, and highgrade astrocytomas (1998) (0)
Radiation is an Important Component of Multimodality Therapy for Pediatric Supratentorial Non-Pineal Neuroectodermal Tumors (2017) (0)
QUANTITATION OF TUMOR UPTAKE OF IODINE-131 USING A CONTRAST DEPENDENT THRESHOLD TECHNIQUE (1994) (0)
259 Radiotherapy for grade II gliomas (1995) (0)
Subject Index Vol. 24, 1996 (1996) (0)
Improving the statistical reliability of stream heat assimilation prediction. Final report (1975) (0)
Prognostic signi cance of an apoptotic index and apoptosis / proliferation ratio for patients with high-grade astrocytomas 1 (2005) (0)
Meta-analysis: Methods, Strengths, and Weaknesses (2000) (0)
AGE AND MOLECULAR SUBGROUPING DETERMINE THE PREDICTIVE VALUE OF PROGNOSTIC MARKERS IN GLIOBLASTOMA MULTIFORME (1999) (0)
Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth rates of either xenograft. (2005) (0)
Advances in Brief Protease Pretreatment Increases the Efficacy of Adenovirus-mediated Gene Therapy for the Treatment of an Experimental Glioblastoma Model 1 (2001) (0)
Recent advances in clinical trial design and analysis (1996) (0)
Expression levels of EGFR in malignant gliomas are associated with response to treatment with the EGFR inhibitor OSI-774 (2004) (0)
Chapter 16 – Clinical Trials (2005) (0)
Radiation Is an Important Component of Multimodality Therapy for Pediatric Supratentorial Neuroectodermal Tumors (2007) (0)
in Breast Cancer Xenografts with Radioimmunotherapy to Increase Efficacy and Apoptosis Integrin Receptor Synergizes (2002) (0)
Genetic Subgroups in Anaplastic Astrocytomas Correlate with Age and Survival (1998) (0)
Prognosis in disseminated prostate cancer as related to tumor ploidy and differentiation (1990) (0)
A Comparison of Flurbiprofen and Aspirin (1999) (0)
Use of response surface statistical designs to detect effects of biologic response modifiers such as IL-2. (1994) (0)
prolifera-Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma (2009) (0)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma 1 Neuro-Oncology (2005) (0)
Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy 1 (2003) (0)
acid (DOTA)-.Peptide-ChL6, a Novel linmunoconjugate with Catabolizable Linker, to 2-Iminothiolane-2- (p-(Bromoacetamido)benzyl)-DOTA-ChL6 in Breast Cancer Xenografts' (1998) (0)
15-year results for upfront TPDCV chemotherapy phase II trial for pediatric low-grade hypothalamic/chiasmatic gliomas (2008) (0)
Treatment of aplastic anaemia with ATGAM® (antithymocyte globulin [equine]) (1984) (0)
Contents, Vol. 24, 1996 (1992) (0)
Genetic classification of grade 3 and grade 4 astrocytoma with DNA microarrays (2004) (0)

This paper list is powered by the following services:

Other Resources About Kathleen Lamborn

en.wikipedia.org

What Schools Are Affiliated With Kathleen Lamborn?

Kathleen Lamborn is affiliated with the following schools: